We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

71 hedge funds and large institutions have $75.4M invested in Invesco Biotechnology & Genome ETF in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 11

0.95% more ownership

Funds ownership: 29.06% → 30.01% (+0.95%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 74 → 71 (-3)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

19% less capital invested

Capital invested by funds: $93.2M → $75.4M (-$17.8M)

Holders
71
Holders Change
-3
Holders Change %
-4.05%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
22
Reduced
11
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
+$6.12M
2
Morgan Stanley
Morgan Stanley
New York
+$2.67M
3
RJA
Raymond James & Associates
Florida
+$1.9M
4
Bank of America
Bank of America
North Carolina
+$1.76M
5
PA
PFG Advisors
Arizona
+$1.59M

Top Sellers

Rank Fund Capital Flow
1
ACM
Arlington Capital Management
Illinois
-$14.3M
2
UBS Group
UBS Group
Switzerland
-$2.23M
3
SG Americas Securities
SG Americas Securities
New York
-$452K
4
BRF
B. Riley Financial
California
-$415K
5
EA
Evanston Advisors
Illinois
-$238K
Name Holding Trade Value Shares
Change 		Change in
Stake
GEA
51
Glen Eagle Advisors
New Jersey
$41.7K – – –
AIC
52
Ameritas Investment Company
Nebraska
$38K +$41.8K +814 New
LDFR
53
Lehman & Derafelo Financial Resources
Pennsylvania
$28K +$30.8K +600 New
FANJ
54
Financial Architects (New Jersey)
New Jersey
$24K – – –
CWA
55
Clarus Wealth Advisors
Arizona
$21K – – –
William Blair & Company
56
William Blair & Company
Illinois
$19K – – –
APA
57
American Portfolios Advisors
New York
$15.3K -$10.3K -200 -38%
FCA
58
FinTrust Capital Advisors
South Carolina
$15K +$16.2K +316 New
RFA
59
Reilly Financial Advisors
California
$14K – – –
CAPTRUST Financial Advisors
60
CAPTRUST Financial Advisors
North Carolina
$12K – – –
ME
61
McIlrath & Eck
Washington
$10K – – –
S
62
SignatureFD
Georgia
$10K – – –
AIM
63
Advantage Investment Management
Iowa
$9K – – –
EWM
64
Elmwood Wealth Management
California
$9K – – –
HWM
65
Holloway Wealth Management
Florida
$9K – – –
ASN
66
Advisory Services Network
Georgia
$8K – – –
Northwestern Mutual Wealth Management
67
Northwestern Mutual Wealth Management
Wisconsin
$5K – – –
GWM
68
Geneos Wealth Management
Colorado
$4K – – –
AIP
69
Ameritas Investment Partners
Nebraska
$2K – – –
DWM
70
Doyle Wealth Management
Florida
$2K +$2.57K +50 New
GT
71
Glenmede Trust
Pennsylvania
$309 +$338K +6,579 New
CAS
72
Cue Advisory Services
Arizona
– -$1.79M -30,178 Closed
SG Americas Securities
73
SG Americas Securities
New York
– -$452K -7,609 Closed
BRF
74
B. Riley Financial
California
– -$415K -6,982 Closed
EA
75
Evanston Advisors
Illinois
– -$238K -4,000 Closed
1 2
3
4

PBE Hedge Fund Activity: Q4 2018 in Review

71 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2018, worth a combined $75.4M — down 19% from $93.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PBE and 13 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 22 added.

The largest buyer was HighTower Advisors, adding an estimated $6.12M. The largest seller was Arlington Capital Management, cutting an estimated $14.3M.

  • 71 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2018, down from 74 in Q3 2018.
  • Funds reported $75.4M of Invesco Biotechnology & Genome ETF stock for Q4 2018, down 19% quarter-over-quarter.
  • 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2018 and 16 closed out, a net change of -3 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2018 was HighTower Advisors, an estimated $6.12M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2018 was Arlington Capital Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q4 2018.